Lanifibranor is an oral pan-PPAR agonist that seems to significantly enhance hepatic and peripheral insulin sensitivity, as demonstrated by reductions in fasting liver glucose production and hepatic insulin resistance (IR) index, as well as by improved insulin-stimulated muscle glucose disposal [172]. Here, INS is linked to Insulin resistance.